Milestone Pharmaceuticals (NASDAQ:MIST) Upgraded by Wall Street Zen to “Hold” Rating

Milestone Pharmaceuticals (NASDAQ:MIST) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Saturday.

Several other brokerages also recently commented on MIST. Zacks Research downgraded Milestone Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, February 24th. HC Wainwright reiterated a “buy” rating and set a $8.00 price target on shares of Milestone Pharmaceuticals in a research report on Tuesday, January 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Milestone Pharmaceuticals in a report on Monday, December 29th. TD Cowen upgraded shares of Milestone Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday, December 15th. Finally, Wells Fargo & Company boosted their price objective on shares of Milestone Pharmaceuticals from $4.00 to $8.00 and gave the company an “overweight” rating in a research note on Tuesday, December 16th. Three analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $8.00.

Milestone Pharmaceuticals Trading Down 9.6%

Shares of MIST stock opened at $1.04 on Friday. The stock has a market capitalization of $88.58 million, a price-to-earnings ratio of -1.32 and a beta of 0.48. The company’s fifty day simple moving average is $1.72 and its two-hundred day simple moving average is $1.97. Milestone Pharmaceuticals has a 1 year low of $0.63 and a 1 year high of $3.06. The company has a debt-to-equity ratio of 1.37, a current ratio of 8.01 and a quick ratio of 8.24.

Milestone Pharmaceuticals (NASDAQ:MIST) last posted its quarterly earnings results on Friday, March 20th. The company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.02. The company had revenue of $1.44 million during the quarter, compared to the consensus estimate of $37.52 million. As a group, analysts anticipate that Milestone Pharmaceuticals will post -0.62 earnings per share for the current year.

Insider Activity

In other news, CEO Joseph Oliveto sold 34,523 shares of the business’s stock in a transaction dated Monday, January 26th. The stock was sold at an average price of $1.93, for a total transaction of $66,629.39. Following the completion of the transaction, the chief executive officer owned 482,744 shares of the company’s stock, valued at approximately $931,695.92. The trade was a 6.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last ninety days, insiders sold 113,693 shares of company stock worth $233,347. Company insiders own 19.50% of the company’s stock.

Institutional Investors Weigh In On Milestone Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of MIST. Propel Bio Management LLC grew its stake in Milestone Pharmaceuticals by 186.1% in the 3rd quarter. Propel Bio Management LLC now owns 5,124,890 shares of the company’s stock worth $10,250,000 after buying an additional 3,333,333 shares in the last quarter. Orbimed Advisors LLC purchased a new stake in shares of Milestone Pharmaceuticals during the 3rd quarter valued at $6,444,000. Simplify Asset Management Inc. raised its position in shares of Milestone Pharmaceuticals by 186.2% during the 3rd quarter. Simplify Asset Management Inc. now owns 2,832,974 shares of the company’s stock valued at $5,666,000 after buying an additional 1,842,974 shares in the last quarter. Marshall Wace LLP lifted its holdings in shares of Milestone Pharmaceuticals by 289.8% during the 4th quarter. Marshall Wace LLP now owns 1,656,821 shares of the company’s stock worth $3,347,000 after acquiring an additional 1,231,793 shares during the last quarter. Finally, Pathstone Holdings LLC bought a new stake in shares of Milestone Pharmaceuticals during the 3rd quarter worth $2,000,000. 86.18% of the stock is owned by hedge funds and other institutional investors.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.